Financial News
Articles published by Veracyte, Inc.
![](https://mms.businesswire.com/media/20230214005701/en/1713354/5/Multi-color_Logo_RGB_Jan_2023.jpg)
![](https://mms.businesswire.com/media/20230213005525/en/1712057/5/Multi-color_Logo_RGB_Jan_2023.jpg)
![](https://mms.businesswire.com/media/20230206005607/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
February 06, 2023
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20230201005995/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20230201005374/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
February 01, 2023
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20221214006009/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
December 15, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20221102005384/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces Third Quarter 2022 Financial Results
November 02, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20221101006302/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20221027006022/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20221025005294/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20221021005480/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
October 24, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20221018006024/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20221013005977/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220921006046/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220913005446/en/1569284/4/John_Leite_Headshot_Cropped.jpg)
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
September 13, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220910005029/en/1567707/4/4715802cVeracyte_RGB_LRG_H.jpg)
![](https://mms.businesswire.com/media/20220907005588/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220901005317/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 01, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220831005288/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220828005032/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220811005740/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
August 11, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220802005901/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
Veracyte Announces Second Quarter 2022 Financial Results
August 02, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220720006005/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220714005808/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220713005843/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220627005197/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220620005115/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
June 20, 2022
From Veracyte, Inc.
Via Business Wire
Tickers
VCYT
![](https://mms.businesswire.com/media/20220603005121/en/791654/5/Veracyte_RGB_LRG_H_registered.jpg)
![](https://mms.businesswire.com/media/20220531005991/en/633623/4/Veracyte_RGB_LRG_H.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.